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Brief Definit ive Report
Constitutive activation of the PI3K pathway is 
very common in cancer, and PI3K inhibitors 
are currently progressing through oncology tri-
als (Rodon et al., 2013). At present, the role of 
PI3K in the tumor microenvironment, such as 
in cancer-associated fibroblasts, endothelial cells 
(ECs), mural cells, and immune cells, is largely 
unexplored. With the exception of white blood 
cells, where p110 and p110 both play impor-
tant roles (including in cancer; p110; Schmid 
et al., 2011), the ubiquitously expressed p110 
is likely to be a critical PI3K isoform in non-
leukocyte stromal cell types, based on the no-
tion that p110 plays a nonredundant key role 
in vascular development (Lelievre et al., 2005; 
Graupera et al., 2008) and fibroblast prolifera-
tion (Foukas et al., 2006; Zhao et al., 2006). 
However, the role of p110 in the tumor stroma 
is unknown. To assess the importance of the 
p110 PI3K axis in the cancer stromal com-
partment, we manipulated this pathway in syn-
geneic mouse cancer models.
RESULTS AND DISCUSSION
Systemic pharmacological blockade of p110 
and p110 in mice leads to decreased B16F1 
melanoma growth and aberrant angiogenesis
In vitro treatment of B16F1 cells with PI3Ki-A/D, 
a small molecule inhibitor with selectivity for 
p110 and p110 (Edgar et al., 2010), reduced 
Akt phosphorylation (Fig. 1 A), without affecting 
cell proliferation (Fig. 1 B) or survival (Fig. 1 C). 
This compound also reduced in vitro production 
of vascular endothelial growth factor (VEGF) 
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Understanding the direct, tumor cell–intrinsic effects of PI 3-kinase (PI3K) has been a key 
focus of research to date. Here, we report that cancer cell–extrinsic PI3K activity, mediated 
by the p110 isoform of PI3K, contributes in an unexpected way to tumor angiogenesis. In 
syngeneic mouse models, inactivation of stromal p110 led to increased vascular density, 
reduced vessel size, and altered pericyte coverage. This increased vascularity lacked func-
tionality, correlating with enhanced tumor hypoxia and necrosis, and reduced tumor 
growth. The role of p110 in tumor angiogenesis is multifactorial, and includes regulation 
of proliferation and DLL4 expression in endothelial cells. p110 in the tumor stroma is thus 
a regulator of vessel formation, with p110 inactivation giving rise to nonfunctional 
angiogenesis, which can stunt tumor growth. This type of vascular aberration differs from 
vascular endothelial growth factor–centered antiangiogenesis therapies, which mainly lead 
to vascular pruning. Inhibition of p110 may thus offer a new antiangiogenic therapeutic 
opportunity in cancer.
© 2013 Soler et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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Figure 1. p110 inhibition reduces in vivo growth of B16F1 melanoma tumors. (A) B16F1 cells were treated for 1 h with compounds or vehicle, 
followed by immunoblotting of total cell lysate using the indicated antibodies (n = 3). (B) In vitro proliferation (n = 3) and (C) cell viability (n = 3) of 
B16F1 cells after 48-h in vitro treatment with vehicle, LY294002, or PI3Ki-A/D. (D) B16F1 cells were treated with test compounds or vehicle, followed  
by quantitation of VEGF secreted into the culture medium (n = 4). (E) Size of B16F1 tumors treated for 16 d with vehicle (n = 10) or PI3Ki-A/D  
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p110 inactivation reduces mural cell coverage  
of B16F1 tumor blood vessels
Compared with B16F1 tumors in WT mice, tumor vessels in 
p110D933A/WT mice showed a clear trend for decreased posi-
tivity for the mural cell marker -SMA (Fig. 2, A, B, and G), 
with enhanced expression of the pericyte markers desmin 
(Fig. 2, C, D, and H) and NG2 (Fig. 2, E, F, and I). PI3Ki-A/D 
had a similar impact (Fig. 2, G–I). In normal tissue, -SMA is 
expressed in the smooth muscle cells of large vessels and rarely 
expressed in capillary pericytes. In cancer, however, capillaries 
are often -SMA+. Conversely, desmin and NG2 are markers 
of normal pericytes, but show a more variable expression in 
tumor-associated pericytes (Armulik et al., 2011). This dimin-
ished positivity of -SMA but strong expression of desmin 
and NG2 suggests a more mature/quiescent pericyte pheno-
type of the PI3K-inhibited vessels. It remains possible, how-
ever, that the observed pericyte alterations upon p110 
inhibition do not have a functional role, but simply correlate 
with the reduced vessel caliber.
p110 inhibition also induces aberrant angiogenesis  
in the CMT19T carcinoma tumor model
Genetic (Fig. 2 J) or pharmacological (Fig. 2 K) inactivation 
of p110 significantly reduced intradermal tumor growth of 
CMT19T lung carcinoma cells in syngeneic mice. The num-
ber of blood vessels in these tumors was substantially increased 
upon stromal inhibition of p110 (Fig. 2, L–N), with a similar 
(but statistically not significant) trend upon treatment with 
PI3Ki-A/D (Fig. 2, P–R). The luminal area of the vessels was 
decreased upon genetic or pharmacological inhibition of p110 
(Fig. 2 O and S). p110 inhibition in CMT19T tumors also 
recapitulated the altered pericyte phenotype observed in the 
B16F1 model, with reduced -SMA staining (Fig. 2 T) and 
increased expression of desmin (Fig. 2 U).
Our observations are in line with the inability of mice 
with EC-specific loss of the p85 PI3K regulatory subunits to 
form large vessels (Yuan et al., 2008). Analogous observations 
have been made in mice with altered activity of Akt, a key 
downstream target of p110. Indeed, tumor vascular density is 
increased in Akt1 KO mice (Chen et al., 2005) and vessel size 
is increased in mice which express a constitutively active Akt1 
transgene (Phung et al., 2006). Together, these data establish a 
p85/p110/Akt1 signaling axis in tumor angiogenesis.
p110 inhibition reduces proliferation  
of tumor-associated ECs
Inactivation of p110 in the tumor stroma reduced PI3K 
signaling in ECs in vivo, as indicated by a decrease in the 
by B16F1 cells (Fig. 1 D). In mice, administration of PI3Ki-A/D 
severely blunted B16F1 tumor growth (Fig. 1 E) without affect-
ing in vivo tumor cell proliferation (Fig. 1, F–H). PI3Ki-A/D– 
treated tumors had increased numbers of CD31-positive 
blood vessels (Fig. 1 I-K) with reduced size, compared with 
vehicle-treated mice (Fig. 1, I, J, and L). This induction by 
PI3Ki-A/D of aberrant angiogenesis, with enhanced vessel 
density and reduced vessel caliber, is likely to contribute to 
the observed reduction in B16F1 tumor growth in vivo.
Stromal inhibition of p110 reduces B16F1 tumor growth 
and increases the density of smaller blood vessels
To investigate the impact of p110 inactivation in the stroma 
only, we inoculated B16F1 cells in mice heterozygous for the 
kinase-dead p110D933A knock-in (KI) allele (Foukas et al., 
2006), further referred to as p110D933A/WT mice. p110D933A/WT 
mice exhibit delayed vascular development, but their vascular 
plexuses are indistinguishable from WT littermates upon reach-
ing adulthood (unpublished data). We also inoculated B16F1 
cells in p110D910A/D910A KI mice (Okkenhaug et al., 2002) 
and in p110D933A/WT/p110D910A/D910A compound KI mice, 
to assess the possible involvement of p110 reactivity of 
PI3Ki-A/D in the biological actions of this compound. Growth 
of B16F1 tumors was significantly reduced in p110D933A/WT 
mice (Fig. 1 M), to a similar extent as observed upon inocula-
tion in p110D933A/WT/p110D910A/D910A KI mice (Fig. 1 N). 
Tumor growth was unaffected in p110D910A/D910A KI mice 
(Fig. 1 N), suggesting that, under the experimental conditions 
tested, p110 inactivation in the tumor stroma, on its own or 
in combination with partial inactivation of p110, does not 
affect B16F1 tumor growth. These observations further imply 
that the antitumor effect of PI3Ki-A/D is mainly a result of 
inhibition of p110.
The number of tumor blood vessels was increased in 
p110D933A/WT mice compared with WT mice (Fig. 1, O–Q), 
with a reduction in vessel luminal area (Fig. 1 R). The PI3Ki-
A/D–induced reduction in vessel area and tumor growth was 
stronger than upon stromal inactivation of p110 (com-
pare Fig. 1 L to Fig. 1 R, and Fig. 1 E to Fig. 1 M), possibly 
related to the reduction in intratumoral VEGF levels upon 
pharmacological intervention (Fig. 1 S). These data suggest 
that both stromal and cancer-intrinsic blockade of p110  
is required for maximal impact on tumor growth and angio-
genesis. It is important to keep in mind, however, that 
p110 activity is only reduced by 50% in the p110D933A/WT 
mice (Graupera et al., 2008), whereas PI3Ki-A/D has the 
capacity to fully block p110 signaling, in both the tumor 
and the stroma.
(n = 10). (F and G) Sections of vehicle- or PI3Ki-A/D–treated B16F1 tumors stained with the indicated antibodies. White and yellow arrows indicate pro-
liferating and nonproliferating cells, respectively. (H) Quantification of in vivo–proliferating B16F1cells. (I and J) CD31-stained sections of vehicle- or 
PI3Ki-A/D–treated B16F1 tumors. (K) Quantification of vessel structures and (L) lumen area of vessels of mice treated with vehicle (n = 10) or PI3Ki-A/D  
(n = 8). (M) Size of tumors inoculated in WT (n = 14) or p110D933A/WT (n = 11) mice. (N) Size of tumors inoculated in WT (n = 7), p110D933A/WT (n = 5), 
p110D910A/D910A (n = 6), or p110D933A/WT/p110D910A/D910A (n = 4) mice. (O and P) CD31-stained sections of tumors inoculated in WT or p110D933A/WT mice. 
(Q) Quantification of vessel structures and (R) lumen area of the vessels in WT (n = 5) or p110D933A/WT (n = 5) mice. (S) Quantitation of VEGF content in 
tumors in control (n = 11), PI3Ki-A/D-treated (n = 5), or p110D933A/WT (n = 8) mice.
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evidence for an impact on EC survival (Fig. 3, E, F, and I). 
Reduced proliferation of tumor-associated ECs upon p110 
inhibition might contribute to diminished vessel size. During 
developmental angiogenesis, partial inactivation of p110 
number of ECs staining positive for phospho-Ser240/244-S6, 
a marker of PI3K pathway activation (Fig. 3, A, B, and G).
Genetic or pharmacological inhibition of p110 led to a 
reduction in EC proliferation (Fig. 3 C, D and H), with no 
Figure 2. p110 inhibition alters mural cell coverage of vessels in B16F1 and CMT19T tumors. (A–F) Sections of B16F1 tumors stained for 
CD31 and -SMA (A and B), desmin (C and D), or NG2 (E and F). (G–I) Quantification of vessels positive for -SMA (G), desmin (H), and NG2 (I) in tumors 
implanted in WT (n = 5) or p110D933A/WT (n = 5) mice and in tumors treated with vehicle (n = 6) or PI3Ki-A/D (n = 6). (J and K) Size of CMT19T tumors 
inoculated in WT (n = 18) or p110D933A/WT (n = 18) mice (J), and of tumors treated with vehicle (n = 9) or PI3Ki-A/D (n = 10; K). (L, M, P, and Q) CD31-
stained sections of tumors inoculated in WT or p110D933A/WT mice (L and M) and of tumors of vehicle- or PI3Ki-A/D–treated mice (P and Q). (N and R) Quanti-
fication of vessel structures in WT (n = 5) or p110D933A/WT (n = 4) mice (N) and of mice treated with vehicle (n = 9) or PI3Ki-A/D (n = 9; R). (O and S) Quantification 
of lumen area of vessels in CMT19T tumors in WT (n = 5) or p110D933A/WT (n = 4) mice (O) or from mice treated with vehicle (n = 9) or PI3Ki-A/D (n = 9; S).  
(T and U) Quantification of -SMA–positive (T) and desmin-positive vessels (U) in tumors implanted in WT (n = 10) or p110D933A/WT (n = 7) mice.
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p110 inhibition reduces tumor blood vessel functionality
To understand the paradox of increased vessel density and 
decreased tumor growth upon p110 inactivation, we tested 
vessel functionality in B16F1 tumors. Tumors in p110D933A/WT 
mice displayed enhanced hypoxia (Fig. 4, A, B, and G) and 
an overall increased tumor cell death (Fig. 4, C, D, and H). 
Likewise, PI3Ki-A/D treatment also led to increased hypoxia 
and necrosis in B16F1 tumors (Fig. 4, G and H). Given that 
B16F1 cells are not sensitive to the direct antiproliferative/
cytotoxic action of PI3K inhibition in vitro (Fig. 1, B and C), 
these observations suggest that the cell death observed in 
tumors is a consequence of unfavorable stromal conditions 
induced by PI3K inhibition. Tumor vessel perfusion, as mea-
sured by monitoring lectin positivity of vessels after intrave-
nous administration of fluorescent lectin, was reduced in 
p110D933A/WT mice (Fig. 4, E, F, and I). Together, these data 
show that reduced p110 activity in the tumor stroma led to 
hypoperfused supernumerary vessels, correlating with im-
paired oxygenation, enhanced tumor cell death, and reduced 
tumor growth.
does not affect EC proliferation (Graupera et al., 2008). In 
the tumor microenvironment, however, ECs may become 
sensitized, given that the vessels in p110D933A/WT mice be-
come aberrant upon tumor cell inoculation, i.e., under stress. 
This difference in impact on angiogenesis under steady-state 
and stressed conditions is not unique to p110, but is also 
observed in many other mouse mutants, including Akt1 and 
Ang2 mutant mice, which show vascular alterations in tu-
mors but not in developmental angiogenesis (Chen et al., 
2005; Nasarre et al., 2009). Of note, changes in pericytes can 
also attenuate EC proliferation (Hirschi and D’Amore, 1997) 
and it is possible that altered p110 signaling in pericytes 
leads to aberrant EC–pericyte cross-talk.
We cannot rule out that reduced EC migration upon 
p110 inhibition (Graupera et al., 2008; Herbert et al., 2009) 
may also contribute to the angiogenesis phenotype observed 
in tumors. Indeed, reducing EC motility may force ECs to 
stay put, which could increase pericyte cell coverage and in-
duce phenotypic changes in these cells, as observed in tissues 
with a slow vascular turnover (Díaz-Flores et al., 2009).
Figure 3. p110 inhibition results in 
reduced PI3K signaling and proliferation 
in B16F1 tumor-associated ECs.  
(A and B) Sections of tumors stained for CD31 
and pSer240/244-S6. White arrowheads indi-
cate ECs that are positive for pSer240/244-S6. 
(C and D) Sections of tumors stained for 
CD31, KI67, and DAPI. Yellow arrows indicate 
Ki67-positive ECs. (E and F) Section of tumors 
stained for CD31 and TUNEL. Boxed regions in 
E and F are shown in the bottom images. 
White arrows indicate TUNEL-positive ECs.  
(G) Quantification of pSer240/244-S6–posi-
tive ECs relative to the total numbers of ECs 
per vessel in tumors in WT (n = 10) or 
p110D933A/WT (n = 28) mice. (H) Quantifica-
tion of Ki67-positive ECs per total number of 
ECs per section area in tumors in WT (n = 4) 
or p110D933A/WT (n = 5) mice and in tumors 
treated with vehicle (n = 5) or PI3Ki-A/D  
(n = 6). (I) Quantification of the TUNEL-positive 
ECs per total number of ECs per section area 
in tumors in WT (n = 4) or p110D933A/WT  
(n = 5) mice and in tumors treated with vehicle 
(n = 6) or PI3Ki-A/D (n = 6).
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(Fig. 1 E). Pan-class I PI3K inhibition also resulted in in-
creased vascular density and reduced vessel size (Fig. 4, K–N) 
and increased tumor hypoxia (Fig. 4, O–Q), suggesting a non-
functional vasculature. The reason for the differences between 
our data and that of Qayum et al. (2009, 2012) is unclear at 
the moment, but may relate to the use of syngeneic versus 
xenograft mouse models. Our data further indicate that p110 
and p110 are not involved in B16F1 tumor growth and 
angiogenesis, given that treatment with PI3Ki-A/D (p110/ 
Our findings differ from previously published studies 
(Qayum et al., 2009, 2012) which showed that pan-class I 
PI3K inhibitors (PI-103 and GDC-0941) induce enhanced 
tumor vascular flow, perfusion, and oxygenation in human 
xenograft cancer models, with no differences in tumor growth, 
vessel density, or size. To clarify this discrepancy, we tested the 
impact of GDC-0941 (which blocks p110, p110, p110, 
and p110) on B16F1 tumors. GDC-0941 was found to in-
hibit tumor growth (Fig. 4 J) to a similar extent as PI3Ki-A/D 
Figure 4. p110 inhibition increases 
B16F1 tumor hypoxia and necrosis and 
reduces vessel perfusion. (A–D) Sections of 
tumors stained for CD31 and pimonidazole (A 
and B) or by TUNEL (C and D). (E and F) Sec-
tions of tumors stained for lectin and CD31. 
Yellow arrows indicate perfused vessels.  
(G) Quantification of the hypoxic area of tumors 
implanted in WT (n = 6) or p110D933A/WT  
(n = 7) mice and in tumors treated with ve-
hicle (n = 22) or PI3Ki-A/D (n = 20). (H) Quan-
tification of the necrotic and apoptotic area in 
tumors implanted in WT (n = 5) or p110D933A/WT 
(n = 5) mice and in tumors treated with  
vehicle (n = 10) or PI3Ki-A/D (n = 9). (I) Quan-
tification of perfused vessels (lectin-positive 
vessels) within the viable area in tumors im-
planted in WT (n = 3) or p110D933A/WT (n = 3) 
mice. (J) Size of tumors treated with vehicle or 
GDC-0941 (n ≥ 8). (K and L) Sections of tu-
mors stained for CD31 after treatment with 
vehicle or GDC-0941. (M) Quantification of 
vessel structures of mice treated with vehicle 
(n = 9) or GDC-0941 (n = 6). (N) Quantifica-
tion of lumen area of vessels in tumors 
treated with vehicle (n = 9) or GDC-0941  
(n = 6). (O and P) Sections of tumors stained 
for CD31 and pimonidazole after treatment 
with vehicle or GDC-0941. (Q) Quantification of 
the hypoxic area relative to the viable area  
of tumors treated with vehicle (n = 9) or 
GDC-0941 (n = 6).
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of DLL4 expression in both tumor cells and ECs. Collectively, 
these data indicate a possible involvement of reduced DLL4 
levels in the nonfunctional angiogenesis induced by p110 
PI3K inhibition. However, the phenotype observed upon 
p110 inhibition is only partially reminiscent of that observed 
upon Notch inhibition. Indeed, whereas Notch inhibition 
leads to a dramatic increase in EC numbers, blocking p110 
activity in tumors results in reduced EC proliferation.
In summary, we report that inhibition of p110 in synge-
neic mouse cancer models led to an increased density of 
smaller, hypoperfused vessels with altered vascular pericyte 
coverage, correlating with enhanced tumor hypoxia and tumor 
cell death. Although a consistent reduction of vessel size was 
observed upon p110 inhibition, the impact on the vessel 
number was more variable. However, it is clear that even 
when the number of vessel structures is increased, this does 
not rescue the reduced functionality of these small vessels. 
These observations suggest that the size of the vessels and not 
their number is the key parameter in the antiangiogenic effect 
of p110 inhibition. The impact of p110 in angiogenesis is 
most likely multifactorial, with reduction of DLL4 expression 
levels being only one aspect of its function, in addition to the 
regulation of EC proliferation, possibly in a Notch-indepen-
dent manner. Strategies that confer sustained antiangiogenesis 
are expected to be essential for effective cancer therapy. The 
data presented here may offer an alternative to the vessel 
pruning strategies which are the mainstay of current antian-
giogenic approaches.
inhibitor) and GDC-0941 (p110/// inhibitor) gave rise 
to a similar reduction in tumor growth and a similar tumor 
vasculature phenotype.
p110 inhibition results in reduced DLL4 expression in ECs
Our data show that blocking p110 supports nonfunctional 
angiogenesis, a phenotype highly reminiscent of that observed 
upon inhibition of the Notch ligand DLL4 (Noguera-Troise 
et al., 2006; Ridgway et al., 2006). The PI3K pathway has 
been documented to positively regulate DLL4 production 
(Liu et al., 2003) and the activity of -secretase which proteo-
lytically cleaves Notch (Takeshita et al., 2007). Conversely, 
Notch signaling stimulates Akt phosphorylation (Wüstehube 
et al., 2010).
WT and p110D933A/WT mouse lung ECs (mLECs) 
showed no differences in DLL4-stimulated Akt phosphoryla-
tion (Fig. 5 A) and induction of the endogenous Notch target 
genes Hes1 and Hey1 (Fig. 5 B). In contrast, genetic interfer-
ence with p110 activity dampened VEGF-A–induced mRNA 
expression of DLL4 in mLECs (Fig. 5 C). B16F1 tumors in-
oculated in p110D933A/WT mice, however, showed no or only 
slight reductions in the levels of DLL4 mRNA (Fig. 5 D) and 
protein (Fig. 5 E). This is most likely due to the fact that 
B16F1 cells produce DLL4 (Fig. 5 F), which masks the DLL4 
present in the ECs. Upon systemic pharmacological inhibi-
tion of p110, however, DLL4 levels in B16 tumors were se-
verely reduced (Fig. 5 G), most likely because of a reduction 
in VEGF levels in the tumors (Fig. 1 S), together with inhibition 
Figure 5. p110 inhibition reduces DLL4 levels in B16F1 tumors. (A) WT and p110D933A/WT mLECs were stimulated with DLL4 for 24 h, followed by 
immunoblotting of total cell lysate using the indicated antibodies (n = 3 for each genotype). (B) Hes1 and Hey1 mRNA levels in WT and p110D933A/WT 
mLECs stimulated with DLL4 (n ≥ 7 of each genotype). (C) DLL4 mRNA levels in WT and p110D933A/WT mLECs stimulated with VEGF-A (n = 6 of each geno-
type). (D) DLL4 mRNA levels in tumors inoculated in WT (n = 6) or p110D933A/WT (n = 7) mice. (E) DLL4 protein levels in tumors implanted in WT or 
p110D933A/WT mice. mLECs were used as a positive control. (F) DLL4 protein levels in cultured B16F1 cells and mLECs. (G) DLL4 protein levels in tumors 
from mice treated with vehicle or PI3Ki-A/D. mLECs were used as a positive control. (A, E, and G) Quantitation shows the relative immunoreactivity of 
each protein, normalized to the level of actin or tubulin.
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Cryostat tissue sections were analyzed using a Hypoxyprobe Plus kit (Natural 
Pharmacia International Inc). For quantification purposes, only viable, non-
necrotic areas (as determined by DAPI staining and assessment of altered nu-
clear morphology) of the tumor were considered.
Systemic perfusion of fluoresceinated lectin to visualize functional blood 
vessels was performed by injecting of 0.025 mg of fluorescence-labeled to-
mato lectin (FL-1171; Vector Laboratories) into the tail vein in a total volume 
of 50 µl. 3 min later, the mice were sacrificed by cervical dislocation, and 
tissue samples were prepared for OCT-embedded frozen sectioning. Tumor 
tissue was isolated and processed for immunostaining as described above. The 
number of lectin-perfused vessels and total number of vessels present in the 
entire viable area of each tumor section was counted.
Quantitative RT-PCR (qPCR) analysis. qPCR was performed using the 
following proprietary TaqMan Gene Expression assay FAM/TAMRA primers 
(Applied Biosystems): DLL4 (Mm00446968_m1), Hes1 (Mm01342805_m1), 
Hey1 (Mm00468865), and HPRT (Mm00446968_m1). The data show the 
2CT values.
Measurement of  VEGF. Exponentially growing B16F1 cells were incubated 
for 48 h with LY294002 (10 µM), PI3Ki-A/D (0.3 µM), IC87114 (5 µM), or 
vehicle. Medium was collected, centrifuged at 1,000 rpm for 5 min and 
VEGF concentration measured using a Quantikine Mouse VEGF immuno-
assay (R&D Systems) according to the manufacturer’s instructions. This im-
munoassay was also used to measure VEGF in tumor extracts prepared by 
mincing tumors in 1 ml of PBS, followed by harvesting of the soluble fraction 
by centrifugation at 5,000 g for 5 min.
Isolation of ECs. Mouse lung ECs (mLECs) were isolated, purified, and 
cultured as previously described (Potente et al., 2007). In brief, mLECs were 
positively selected with anti–mouse vascular endothelial-cadherin (BD) anti-
body coated with magnetic beads (Invitrogen). Cells were cultured on gela-
tin-coated culture dishes in D-MEM/F12 supplemented with 20% fetal calf 
serum and endothelial cell growth factor (Promocell). After the first passage, 
the cells were repurified with vascular endothelial-cadherin antibody-coated 
magnetic beads.
Stimulation of mLECs. For DLL4 stimulation, mouse DLL4 (500 ng/ml) 
was immobilized by coating culture dishes for 1 h at 37°C, followed by seed-
ing mLECs for 24 h. For stimulation with VEGF-A, mLECs were seeded in 
6-well plates and starved in DMEM without FBS, and endothelial cell growth 
factor for 16 h, followed by stimulation with VEGF-A (200 ng/ml) for 2 h.
Statistical analysis. Statistical analysis was performed by nonparametric 
Mann Whitney’s test or ANOVA test using Prism 5 (GraphPad Software 
Inc.). In all figures across the manuscript, errors bars are standard error of the 
mean. In all cases *, P < 0.05; **, P < 0.01; and ***, P < 0.001 were consid-
ered statistically significant.
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MATERIALS AND METHODS
Mice. Mice were kept in individually ventilated cages and cared for accord-
ing to the guidelines and legislation of the UK Home Office and Catalan 
Departament d’ Agricultura, Ramaderia i Pesca, with procedures accepted by 
the Ethics Committees of Queen Mary University of London and IDIBELL-
CEEA. All KI mice were backcrossed onto the C57/BL6 background for 
>10 generations and WT littermates used as controls. The C57/BL6 mice for 
pharmacological studies were obtained from Charles River UK.
Reagents. VEGF-165 (referred to as VEGF-A in the text) was purchased 
from PeproTech. Sources of antibodies were as follows: Cell Signaling Tech-
nology: Total Akt, pS473-Akt, and pSer240/244-S6; BD: CD31; NeoMarkers: 
Ki67; EMD Millipore: NG2 (AB5320); Abcam: desmin (ab15200); R&D: 
DLL4 (AF1389); Santa Cruz Biotechnology, Inc.: VE-cadherin (sc-6458); 
Sigma-Aldrich: -SMA (C-6198), -actin (A5441), and -tubulin (T6074). 
All chemicals, unless otherwise stated, were purchased from Sigma-Aldrich. 
Secondary antibodies conjugated to Alexa Fluor 488 and Alexa Fluor 568 
were obtained from Molecular Probes. PI3Ki-A/D and GDC-0941 were 
obtained from Genentech.
In vitro measurement of B16F1 cell proliferation and viability. 
B16F1 cells (105/well) were seeded onto 6-well plates 24 h before the ad-
dition of test compounds or vehicle (DMSO), followed by analysis of cell 
number and viability using an automatic cell counter, CASY model TT 
(Innovatis), 48 h later. LY294002 and PI3Ki-A/D were used at 10 µM and 
0.3 µM, respectively.
Protein extraction and immunoblotting. B16F1 cells were plated in 
60 cm2 dishes at 0.5 × 106 cells per dish. 24 h later, cells were treated for 1 h 
with vehicle (DMSO), LY294002 (10 µM), PI3Ki-A/D (0.3 µM), or IC87114 
(5 µM) and lysed in 50 mM Tris-HCl pH 7.4, 5 mM EDTA, 150 mM NaCl, 
50 mM NaF and 1% Triton X-100 supplemented with 2 mg/ml aprotinin, 
1 mM pepstatin, 1 ng/ml leupeptin, 1 mM phenylmethylsulfonylfluoride, and 
1 mM sodium orthovanadate, followed by clearance of lysates by microcen-
trifugation. Supernatants were resolved on a 10% SDS-PAGE gel, transferred 
onto PVDF membranes, and probed with the indicated antibodies. Detec-
tion was performed by enhanced chemiluminescence.
Tumor studies in mice. Age- and sex-matched mice were given a single 
intradermal injection (50 µl) in the flank of 2 × 105 B16F1 or 5 × 105 
CMT19T cells, followed by tumor isolation 2 wk later. For drug treatment, 
8-wk-old WT females were given PI3Ki-A/D (75 mg/kg/day), GDC-0941 
(100 mg/kg/day), or vehicle (0.5% (wt/vol) methylcellulose and 0.2% 
(wt/vol) polysorbate 80 in de-ionized water by oral gavage for 16 d. Drug 
administration started two days before tumor cell inoculation, and had no ad-
verse impact on mouse viability and weight over the 16 d treatment period.
Histological analysis. Fresh tumor tissue was snap-frozen and cryosections 
made. Antibodies used for immunostaining were anti-CD31 (1:100), anti-
Ki67 (1:50), anti--SMA (1:200), anti-NG2 (1:100), anti-desmin (1:150), 
pSer240/244-S6 (1:100). For immunofluorescence detection, Alexa Fluor 
488 goat anti–rat IgG, Alexa Fluor 568 goat anti–rabbit IgG (H + L) and Alexa 
Fluor 568 goat anti–rat IgG were used at a dilution of 1:200. For nuclear 
counterstaining, DAPI (1:5,000) was added in the last PBS wash, followed by 
mounting of the sections in Mowiol. Blood vessel density and vessel area 
were quantified by counting the total number of CD31-positive vessels per 
field across the areas of viable tumor in each section (≥5 tumors/genotype 
and 4 images/tumor). Quantification of in vivo–proliferating tumor cells as 
assessed by the number of Ki67-positive cells relative to the number of 
DAPI-positive cells within the tumor of mice treated with vehicle was per-
formed by counting 100 independent tumor cells per section. Coverage by 
mural cells is expressed as a percentage of vessels positive for -SMA, NG2, 
or desmin per CD31-positive vessels.
Hypoxia in tissue was detected after intraperitoneal injection of 60 mg/kg 
pimonidazole, followed 1 h later by sacrifice of the mice by cervical dislocation. 
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